MOTS-C

Research-centric overview

Peptide

Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).

Community effect votes, structured logs, and side-effect summaries.

No effect profile data seeded yet for this peptide.

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Apr 17, 2026

Studies indexed

Human

Animal

AI analyzed

Evidence mix33% human · 33% animal · 0% cellular · 0% review

Highest phase: PreclinicalYears covered: 2023

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/ObesityClinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the efficacy, safety, and pharmacodynamics of MOTS-C in adults with prediabetes and overweight/obesity. The study was a Phase 2a, randomized, double-blind, placebo-controlled trial. Not reported in abstract.

Phase: PHASE2Status: RECRUITING

High On-treatment Platelet Reactivity, Increased B-amyloid and Downregulation of MOTS-c Predict Mortality in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus: a 2-year Follow up StudyClinical TrialClinicalTrials.govApr 16, 2026

This study evaluated the relationship between on-treatment platelet reactivity, B-amyloid levels, and MOTS-C downregulation in patients with coronary artery disease and type 2 diabetes mellitus over a two-year follow-up period. The findings suggest associations with mortality, but specific numeric outcomes are not detailed in the abstract. No therapeutic claims are made.

Status: UNKNOWN

Cohort of Universal Newborn Deafness-gene Screening in Nantong City, ChinaClinical TrialClinicalTrials.govApr 16, 2026

Not reported in abstract.

Status: ACTIVE_NOT_RECRUITING

A Pilot Study: The Effect of Longitudinal Exercise Programming in Breast Cancer PatientsClinical TrialClinicalTrials.govApr 16, 2026

This pilot study investigated the effects of longitudinal exercise programming in breast cancer patients. The specific outcomes measured were not detailed in the abstract. The study's findings regarding the impact of exercise on this population remain unspecified.

Phase: NAStatus: COMPLETED

The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular RiskClinical TrialClinicalTrials.govApr 16, 2026

This study assessed the effects of GLP-1 agonists, SGLT2 inhibitors, and their combination on endothelial function, arterial stiffness, and left ventricular deformation in patients with type 2 diabetes at high cardiovascular risk. The specific doses and outcomes measured were not detailed in the abstract. The findings may have implications for cardiovascular health in this patient population.

Status: RECRUITING

Semantic Scholar search for MOTS-CStudySemanticScholarDec 12, 2025

MOTS‑c protects against placental injury via Nrf2 activation in hypoxia‑induced intrauterine growth restriction mice.StudyPubMedDec 12, 2025

MOTS-C may protect against placental injury in a mouse model of hypoxia by activating Nrf2, but further research is needed to confirm these effects in humans.

Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study.StudyPubMedDec 12, 2025

MOTS-C levels may be higher in patients with acute coronary syndrome, but specific outcomes and clinical significance are not detailed in the abstract.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.